Optimising management of patients with hepatitis C virus in the age of direct-acting antivirals: results of a Delphi consensus

• Published in: European review for medical and pharmacological sciences Vol. 22; no. 20; p. 7024
• Main Authors: Di Marco, V, Alberti, A, Angarano, G, Colombo, M, Di Perri, G, Gaeta, G B, Ippolito, G, Mangia, A, Pasqualetti, P, Craxì, A
• Format: Journal Article
• Language: English
• Published: Italy 01.10.2018
• ISSN: 2284-0729

To optimize the management of patients with chronic hepatitis C virus (HCV). We developed two questionnaires to determine Italian healthcare professionals' opinions on the overall management of HCV chronic liver disease and the use of direct-acting antivirals (DAAs) in the treatment of HCV. A Delphi consensus method using the RAND/UCLA appropriateness method was used to determine opinions of an expert panel (EP) of specialists. Overall 443 physicians from 167 Italian centres completed the two questionnaires. The EP confirmed the importance of collaboration with general practitioners (GPs) and HCV testing in high-risk groups, but did not agree on treating patients over 80 years of age with DAAs. Over 90% agreed that it was important to quantify HCV-RNA, determine genotype, and test for anti-HIV and HBsAg before starting DAAs. Transient elastography (FibroScan®) was used by >90% to evaluate the stage of liver fibrosis while serum biomarkers were used by <20%. Adherence to therapy, drug-drug interactions and the possibility of treating advanced liver disease were decisive factors in therapy choice. Monthly monitoring during therapy was considered appropriate and 80% were in favor of HCV-RNA testing 24 weeks after the end of the therapy to confirm sustained virological response (SVR). Over 80% agreed that it was necessary to continue follow-up of patients with advanced fibrosis/cirrhosis. Scientific organizations should review their guideline recommendations to facilitate access to DAAs.